PHILADELPHIA, Oct. 4, 2024 — Carisma Therapeutics Inc. (NASDAQ: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 – 10, 2024.
Exploring Novel Avenues
Poster Presentations Overview:
Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma
Publication Number: 329
Session Date & Time: Friday, Nov. 8, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
Charting New Territories
Poster Presentations Overview:
Title: A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Publication Number: 659
Session Date & Time: Friday, Nov. 8, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
The posters presented at SITC 2024 will be available online in the “Publications” section of Carisma’s website following the start of the poster session.
About Carisma Therapeutics
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company headquarters in Philadelphia, PA. For more information, please visit www.carismatx.com.
Proceeding with Caution
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma’s business, strategy, future operations, cash runway, the advancement of Carisma’s product candidates and product pipeline, and clinical development of Carisma’s product candidates, including expectations regarding timing of initiation and results of clinical trials.
The Unveiling of Carisma Therapeutics Inc.’s Bold Innovations
The Dawn of a New Era
When the sun rises over the biotech landscape, it sometimes unveils hidden gems. Carisma Therapeutics Inc., a company at the forefront of groundbreaking medical innovation, has been quietly orchestrating a revolution in the sector. With a visionary approach and a commitment to excellence, Carisma is redefining the boundaries of what’s possible in the field of therapeutics.
A Beacon of Hope Amidst Uncertainty
In a world rife with risks and uncertainties, Carisma stands tall as a beacon of hope. As investors tread cautiously through the ever-shifting sands of financial markets, Carisma’s solid performance and unwavering dedication to progress provide a glimmer of stability. The company’s commitment to transparency and forward-thinking strategies sets it apart in an environment where certainty is a rare commodity.
Redefining Possibilities in the Biotech Sphere
Carisma’s journey echoes the tales of the titans of the biotech world. From humble beginnings to meteoric rises, the company’s evolution speaks volumes about the importance of perseverance and ingenuity in a field defined by challenges. By constantly pushing the boundaries of what is achievable, Carisma is writing a new chapter in the annals of medical science.